FDA Approves Companion Diagnostic For Detection Of Defined Mutations Of EGFR Gene In Patients With NSCLC

Cancer Network (10/30, Slater) reported the FDA “approved expanded claims for the Cobas EGFR Mutation Test v2 as a companion diagnostic for a broader group of therapies in the treatment of non-small cell lung cancer (NSCLC), according to Roche, the develo...